Allergan puts Vraylar on blockbuster track with new bipolar depression nod

Allergan, badly in need of good news, finally has some to share with investors.

Tuesday, the FDA green-lighted the company’s antipsychotic med Vraylar to treat depression in adults with bipolar disorder. The OK makes the drug the first of its kind to treat the full spectrum of symptoms in bipolar I, one of four main types of the mood-shifting disease.